Molecular Interplay between microRNA-34a and Sirtuin1 in Hyperglycemia-Mediated Impaired Angiogenesis in Endothelial Cells: Effects of Metformin

Gnanapragasam Arunachalam, Arun Prasath Lakshmanan, Samson Mathews Samuel, Chris R. Triggle, and Hong Ding

Departments of Pharmacology (G.A., A.P.L., S.M.S.) and Medical Education (C.R.T., H.D.), Weill Cornell Medicine-Qatar, Education City, Doha, Qatar (C.T.)

Received June 22, 2015; accepted November 10, 2015

ABSTRACT

Impaired angiogenesis is a prominent risk factor that contributes to the development of diabetes-associated cardiovascular disease. MicroRNAs (miRNAs), small noncoding RNAs, are implicated as important regulators of vascular function, including endothelial cell differentiation, proliferation, and angiogenesis. In silico analysis and in vitro studies indicate that silent information regulator 1 (SIRT1) is a potential target for endothelial cell–specific miRNAs. In this study, we investigated the molecular crosstalk between miR-34a, the protein product of SIRT1 (sirtuin1), and the anti-diabetic drug, metformin, in hyperglycemia-mediated impaired angiogenesis in mouse microvascular endothelial cells (MMECs). MMECs were cultured, transfected with either a miR-34a inhibitor or mimic in normal glucose (11 mM) or high glucose (HG, 40 mM) in the presence or absence of metformin. The expression of miR-34a, sirtuin1, and their signaling targets was evaluated. miR-34a expression is upregulated in a hyperglycemic milieu and parallels changes in the expression of sirtuin1, post-translational modification of endothelial nitric oxide synthase (phospho/acetylation), as well as an impairment in angiogenesis. The presence of metformin, or the inhibition of miR-34a using an anti–miR-34a inhibitor, increases the expression of sirtuin1 and attenuates the impairment in angiogenesis in HG-exposed MMECs. In contrast, overexpression of a miR-34a mimic prevents metformin-mediated protection. These data indicate that miR-34a, via the regulation of sirtuin1 expression, has an anti-angiogenic action in MMECs, which can be modulated by metformin. In summary, miR-34a represents both a target whereby metformin mediates its vasculoprotective actions and also a potential therapeutic target for the prevention/treatment of diabetic vascular disease.

Introduction

The global increase in the prevalence of type 2 diabetes (T2DM) and the link to an elevated risk for both cardiovascular disease (CVD) and cancer are major concerns that heighten the need for improved approaches for the early detection, prevention, and treatment of T2DM (Tremblay and Hamet, 2015). Vascular endothelial cells (ECs) play a major role in maintaining normal cardiovascular homeostasis, and endothelial dysfunction is recognized as an early indicator of diabetes-associated CVD (Ding and Triggle, 2010; Eelen et al., 2015). The diabetic milieu, namely hyperglycemia, excess free fatty acid release, and insulin resistance, initiates a sequence of events in the vasculature that includes oxidative stress, impaired endothelial function, increased inflammation, and impaired angiogenesis (Avogaro et al., 2011; Roberts and Porter, 2013; Sena et al., 2013). Despite the known high risk for patients with diabetes to develop CVD, the pathogenesis underlying the relationship between T2DM and CVD is not fully understood. Therefore, the identification of new molecular targets that are associated with the development of vascular dysfunction in diabetes is of high scientific interest.

MicroRNAs (miRNAs) are short (~22 nucleotides) noncoding RNAs that typically bind to 3’ untranslated regions of mRNAs, acting principally at the post-transcriptional level and repressing the mRNA translation and stability (Olson, 2014). miRNAs have been implicated as key elements playing crucial roles in the pathogenesis of diabetes-associated CVD, including endothelial dysfunction, angiogenesis, hypertrophy, and heart failure (Urbich et al., 2008; Leeper and Cooke, 2011; Hata, 2013; Beltrami et al., 2014; Arunachalam et al., 2015; Zhu and Leung, 2015). Several endothelial-specific miRNAs have been identified as regulators of cardiac and endothelial function and linked to the regulation of angiogenesis and the development of senescence and inflammation (Suárez and Sessa, 2009; Caporali et al., 2011; Staszel et al., 2011;
Zampetaki and Mayr, 2012; Arunachalam et al., 2015). MicroRNA-34a (miR-34a) is highly expressed in ECs and has been reported to play a key role in the regulation of EC proliferation, inflammation, senescence, and apoptosis (Qin et al., 2012; Badi et al., 2014; Fan et al., 2015). Elevated miR-34a expression has been reported in senescent human umbilical vein ECs as well as in the heart and spleen of aged mice (Ito et al., 2010).

Silent information regulator 1 (SIRT1), referred to as an anti-ageing gene, has been described as a novel regulatory switch in vascular EC homeostasis (Potente et al., 2007; Potente and Dimmeler, 2008). Furthermore, sirtuin1, the protein product of SIRT1, via the deacetylation of endothelial nitric oxide synthase (eNOS), increases the generation of nitric oxide and enhances endothelium-dependent vasodilation (Mattagajasingh et al., 2007; Arunachalam et al., 2010). miR-34a directly binds to SIRT1 through a miR-34a binding site within the 3’ untranslated regions of SIRT1, inhibits the expression of the protein sirtuin1, and regulates apoptosis via the sirtuin1-p53 pathway (Yamakuchi et al., 2008). In human umbilical vein ECs, the overexpression of miR-34a down-regulates sirtuin1 expression and induces EC senescence, whereas the knockdown of miR-34a enhances the expression of sirtuin1 and attenuates endothelial senescence (Ito et al., 2010). In addition, several studies have highlighted miR-34a as an important mediator of age-related cardiac dysfunction by modulating the expression of sirtuin1 (Tabuchi et al., 2012; Boon et al., 2013; Han et al., 2015). Furthermore, the overexpression of miR-34a in endothelial progenitor cells reduces the expression of sirtuin1 expression, resulting in senescence and impaired angiogenesis (Zhao et al., 2010).

Metformin is the first-line oral antidiabetic drug reported to protect endothelial function and the cardiovascular system against the impact of diabetes (UK Prospective Diabetes Study Group, 1998; Sena et al., 2011; Arunachalam et al., 2014; Triggle and Ding, 2014). The assumed primary target for mediating the antidiabetic actions of metformin is AMP-activated protein kinase (AMPK); however, other targets have been implicated, and a potential link between the therapeutic benefits of metformin and the modulation of miRNAs has also been reported and may explain the apparent benefits of metformin in reducing the incidence of certain types of cancer (Blandino et al., 2012; Foretz et al., 2014). However, although the relative importance of sirtuin1, miR-34a, and metformin in the regulation of endothelial function is recognized, the interplay between them and their roles in modulating the effects of hyperglycemia on endothelial function has not been exploited. In the present study, we have investigated the interactions between miR-34a and sirtuin1, as well as miR-34a, as a potential therapeutic target for metformin in the attenuation of hyperglycemia-mediated impaired angiogenesis in mouse microvascular ECs (MMECs).

Materials and Methods

Chemicals. Unless otherwise stated, all chemicals used were of analytical grade and purchased from Sigma-Aldrich (St. Louis, MO). MicroRNA-34a (miR-34a) is highly expressed in ECs and has been reported to play a key role in the regulation of EC proliferation, inflammation, senescence, and apoptosis (Qin et al., 2012; Badi et al., 2014; Fan et al., 2015). Elevated miR-34a expression has been reported in senescent human umbilical vein ECs as well as in the heart and spleen of aged mice (Ito et al., 2010).

Silent information regulator 1 (SIRT1), referred to as an anti-ageing gene, has been described as a novel regulatory switch in vascular EC homeostasis (Potente et al., 2007; Potente and Dimmeler, 2008). Furthermore, sirtuin1, the protein product of SIRT1, via the deacetylation of endothelial nitric oxide synthase (eNOS), increases the generation of nitric oxide and enhances endothelium-dependent vasodilation (Mattagajasingh et al., 2007; Arunachalam et al., 2010). miR-34a directly binds to SIRT1 through a miR-34a binding site within the 3’ untranslated regions of SIRT1, inhibits the expression of the protein sirtuin1, and regulates apoptosis via the sirtuin1-p53 pathway (Yamakuchi et al., 2008). In human umbilical vein ECs, the overexpression of miR-34a down-regulates sirtuin1 expression and induces EC senescence, whereas the knockdown of miR-34a enhances the expression of sirtuin1 and attenuates endothelial senescence (Ito et al., 2010). In addition, several studies have highlighted miR-34a as an important mediator of age-related cardiac dysfunction by modulating the expression of sirtuin1 (Tabuchi et al., 2012; Boon et al., 2013; Han et al., 2015). Furthermore, the overexpression of miR-34a in endothelial progenitor cells reduces the expression of sirtuin1 expression, resulting in senescence and impaired angiogenesis (Zhao et al., 2010).

Metformin is the first-line oral antidiabetic drug reported to protect endothelial function and the cardiovascular system against the impact of diabetes (UK Prospective Diabetes Study Group, 1998; Sena et al., 2011; Arunachalam et al., 2014; Triggle and Ding, 2014). The assumed primary target for mediating the antidiabetic actions of metformin is AMP-activated protein kinase (AMPK); however, other targets have been implicated, and a potential link between the therapeutic benefits of metformin and the modulation of miRNAs has also been reported and may explain the apparent benefits of metformin in reducing the incidence of certain types of cancer (Blandino et al., 2012; Foretz et al., 2014). However, although the relative importance of sirtuin1, miR-34a, and metformin in the regulation of endothelial function is recognized, the interplay between them and their roles in modulating the effects of hyperglycemia on endothelial function has not been exploited. In the present study, we have investigated the interactions between miR-34a and sirtuin1, as well as miR-34a, as a potential therapeutic target for metformin in the attenuation of hyperglycemia-mediated impaired angiogenesis in mouse microvascular ECs (MMECs).
An antibody against eNOS (1:40 dilution; Cell Signaling, Danvers, MA) was added to 100 μg cellular proteins in a final volume of 400 μl, and incubated for 1 hour. Protein-A/G agarose beads (20 μl; Santa Cruz Biotechnology, Santa Cruz, CA) were added to each sample and kept overnight at 4°C on a rocker. The beads were washed three times and then resuspended in 40 μl radioimmunoprecipitation assay buffer. The immunoprecipitated eNOS agarose bead suspension was resolved by 7.5% SDS-PAGE. To assess the acetylation of eNOS, the membranes were first probed against acetyl lysine antibody (mouse monoclonal acetyl lysine; Cell Signaling) and then reprobed for eNOS (rabbit anti-eNOS; Cell Signaling).

**In Vitro Angiogenesis (Tube Formation) Assay.** The in vitro angiogenic activity of MMECs was determined by Matrigel tube formation assay. Briefly, after the experimental period described above, MMECs were stained with cell-permeable dye, calcein (2 mg/ml; Invitrogen), for 30 minutes and replated in 24-well plates precoated with 150 μl/well growth factor–reduced Matrigel (Geltrex; Invitrogen) and incubated at 37°C in cell culture incubator. After 12 hours of incubation, capillary-like tube formation was observed with a computer-assisted microscope (EVOS, Thermo Fisher Scientific, MA). Tube formation was defined as a tube-like structure exhibiting a length four times its width. Images of tube morphology were taken in 10 random microscopic fields per sample at original magnification, 10×. The numbers of branch points in duplicate wells were counted and averaged using ImageJ software (National Institutes of Health).

**Statistical Analysis.** All data were analyzed by statistical software GraphPad Prism 5.0 (San Diego, CA). Statistical analysis was performed by using one-way analysis of variance. Post hoc comparisons between the groups were performed by Tukey’s multiple comparisons test. Results are presented as mean ± S.E.M. with *P < 0.05 used to indicate statistical significance.

### Results

**Hyperglycemia-Mediated miR-34a Induction Causes Changes in Expression of Sirtuin1, eNOS, and Impaired Angiogenesis in ECs.** Exposure of MMECs to HG for 48 hours showed a significant increase in miR-34a expression, and there was no significant difference in miR-34a expression compared with the osmotic control (11 mM glucose plus 29 mM mannitol) (Fig. 1A). Therefore, we have investigated whether endothelial dysfunction in HG-exposed MMECs can be prevented by decreasing the expression of miR-34a to that comparable in NG-cultured MMECs using a miR-34a inhibitor. MMECs were transfected with either a miR-34a inhibitor or a scrambled control and incubated with HG and NG for 48 hours. As shown in Fig. 1B, the miR-34a inhibitor significantly decreased the expression of miR-34a in both NG- and HG-treated MMECs when compared with scrambled control (*P < 0.05). To further investigate the effects of miR-34a inhibition on ECs, we examined the expression levels of sirtuin1, eNOS, and eNOS phosphorylation. As shown in Fig. 1, C–G, comparing with NG, the exposure of...
MMECs to HG (that were transfected with scrambled control) resulted in a significant ($P < 0.05$) reduction of sirtuin1 expression, which was paralleled by a decrease in eNOS phosphorylation (Ser$^{1177}$), increased eNOS phosphorylation (Thr$^{495}$), and increased eNOS acetylation. Inhibition of miR34-a in HG-treated MMECs transfected with the miR-34a inhibitor resulted in a significant ($P < 0.05$) increase in sirtuin1 expression together with enhanced peNOS level (Ser$^{1177}$), reduced eNOS acetylation, and eNOS phosphorylation at Thr$^{495}$.

Based on the finding that sirtuin1 and eNOS downregulation were associated with impaired angiogenesis in ECs, we further examined the effects of miR-34a inhibition on the expression of the effectors/mediators of angiogenesis Ang-1, Ang-2, and TSP-1. As shown in Fig. 2, A and C–E, the exposure to HG resulted in a significant ($P < 0.05$) reduction in Ang-1 expression along with significant ($P < 0.05$) increases in Ang-2 and TSP-1 levels in MMECs compared with MMECs exposed to NG after both transfected with scrambled control miRNA. Furthermore, MMECs transfected with the miR-34a inhibitor and maintained in HG showed significant increases in Ang-1 expression along with a decrease in Ang-2 and TSP-1 levels compared with those transfected with scrambled control. Importantly, tube-forming activity (Fig. 2, B and F) was also significantly impaired in MMECs that were transfected with negative control miRNA in HG when compared with MMECs maintained in NG; however, MMECs transfected with the miR-34a inhibitor in HG showed a significant ($P < 0.05$) increase in tube-forming activity versus those transfected with the scrambled control. Thus, these results indicate that,

![Image of Fig. 2](https://example.com/fig2.jpg)

**Fig. 2.** Effect of exposure to HG on Ang-1, Ang-2, TSP-1 expression, and angiogenesis in ECs. MMECs were transfected with either scrambled control or a miR-34a inhibitor and, after 12 hours of transfection, cells were exposed to media consisting of either NG or HG for another 48 hours. Ang-1, Ang-2, and TSP-1 expression were determined by immunoblotting. (A and C–E) Representative gel images and histogram values represent mean ± S.E.M. of relative intensity of Ang-1, Ang-2, and TSP-1 levels ($n = 4$). (B and F) Capillary-like tube formation was assessed by matrigel angiogenesis assay. Histogram values represent mean ± S.E.M. of percentage of branch points ($×10$, scale bar: 1000 μm). *($P < 0.05$), significant when compared with control scrambled miRNA. #($P < 0.05$), significant when compared with scrambled miRNA.
in MMECs, miR-34a induction by HG results in a reduction in the expression of sirtuin1 and phosphorylation of eNOS along with impaired angiogenesis that can be reversed by inhibition of miR-34a.

**Metformin Modulates miR-34a, Sirtuin 1, and eNOS, and Attenuates Hyperglycemia-Mediated Impaired Angiogenesis in ECs.** We have previously reported that metformin attenuates hyperglycemia-induced endothelial senescence via a mechanism that involves the upregulation of sirtuin1 and its downstream signaling pathway in MMECs (Arunachalam et al., 2014). However, it is not known whether miR-34a mediates the protective effects of metformin on sirtuin1 expression and EC function in HG. To investigate this potential relationship, MMECs were cultured in media containing either NG or HG alone or with metformin for 48 hours, and changes in the expression of miR-34a, sirtuin1, and eNOS were assessed by quantitative immunoblotting. As shown in Fig. 3, miR-34a expression was significantly \( P < 0.05 \) increased in MMECs exposed to HG for 48 hours with a parallel reduction in sirtuin1 and eNOS phosphorylation levels as well as a subsequent increase in eNOS acetylation, as previously shown (Fig. 1). When MMECs were exposed to HG together with metformin, there was a significant \( P < 0.05 \) reduction in the expression of miR-34a accompanied by a parallel increase in the expression of sirtuin1 and eNOS phosphorylation at Ser^1177, as well as a decrease in the acetylation of eNOS when compared with MMECs exposed to HG alone \( (P < 0.05) \).

To further investigate the interplay between metformin, miR-34a and endothelial function experiments were designed to determine the effects of the metformin-mediated reduction in miR-34a on the effectors/mediators of angiogenesis: namely Ang-1, Ang-2, and TSP-1. As shown in Fig. 4, A and C–E, exposure of MMECs to HG resulted in a significant \( (P < 0.05) \) reduction in Ang-1 expression along with an increase in Ang-2 and TSP-1 expression when compared with MMECs exposed to NG. In contrast, MMECs exposed to HG together with metformin showed a significant \( (P < 0.05) \) increase in Ang-1 expression with diminished Ang-2 and TSP-1 expression. Tube-forming activity (Fig. 4, B and F) was also decreased in MMECs exposed to HG when compared with MMECs exposed to NG, whereas MMECs exposed to HG together with metformin showed a significant increase in tube-forming activity. These results indicate that metformin reduces miR-34a expression, increases the expression of sirtuin1, and enhances eNOS phosphorylation at Ser^1177, as well as attenuating hyperglycemia-induced impaired angiogenesis.

**Overexpression of miR-34a Reduces the Metformin-Mediated Attenuation of Impaired Angiogenesis in HG-Exposed ECs.** To further investigate whether the endothelial-protective action of metformin was miR-34a–dependent, the effect of metformin in MMECs wherein miR-34a had been overexpressed using a miR-34a mimic was examined in NG versus HG conditions. In MMECs transfected with a miR-34a mimic and exposed to either NG or HG, there was a significant increase in miR-34a expression, which remained elevated despite the presence of metformin, whereas, in comparison, in MMECs transfected with scrambled control, there was a reversal of HG-induced upregulation of miR-34a expression after treatment with metformin \( (P <

![Fig. 3. Effect of treatment with metformin on expression of miR-34a, sirtuin1, and eNOS in ECs exposed to HG. MMECs were cultured in media consisting of either NG or HG for 48 hours in the presence or absence of metformin (50 \( \mu \)M). Cell lysates were subjected for analyses of miR-34 expression by quantitative real-time polymerase chain reaction and sirtuin1, peNOS (Ser^1177), eNOS, Ac-Lys, and \( \beta \)-actin by immunoblotting. (A) Histogram values represent mean ± S.E.M. of relative miR-34a expression (normalized to U6 small nuclear RNA, \( n = 4 \)). (B–E) Representative gel images and histogram values represent mean ± S.E.M. of relative intensity of sirtuin1, peNOS, and acetylated eNOS levels (\( n = 4 \)). \( \Psi(P < 0.05) \), significant when compared with NG. \( \#(P < 0.05) \), significant when compared with HG alone."


Fig. 4. Effect of treatment with metformin on expression of Ang-1, Ang-2, TSP-1, and angiogenesis in ECs. MMECs were cultured in media consisting of either NG or HG for 48 hours in the presence or absence of metformin (50 µM). The expression of Ang-1, Ang-2, and TSP-1 was determined by immunoblotting. (A and C–E) Representative gel images and histogram values represent mean ± S.E.M. of relative intensity of Ang-1, Ang-2, and TSP-1 levels (n = 4). (B and F) Capillary-like tube formation was accessed by matrigel angiogenesis assay. Histogram values represent mean ± S.E.M. of percentage of branch points (×10, scale bar: 1000 µM). * (P < 0.05), significant when compared with NG. # (P < 0.05), significant when compared with HG alone.

Discussion

The present study documents that treatment of MMECs with metformin inhibits the expression of miR-34a, with the subsequent increase in the levels of sirtuin1 and active phosphorylated eNOS at Ser1177 leading to the restoration/revival of the angiogenic capacity in HG-exposed MMECs. Diabetes/Hyperglycemia with subsequent oxidative stress has been implicated as the main cause of endothelial dysfunction and resultant cardiovascular disease (Ding and Triggle, 2010; Giacco and Brownlee, 2010). A healthy endothelium is important for the maintenance of angiogenesis; however, much less studied is the role of hyperglycemia in the development of aberrant angiogenesis, a key contributor to many diabetes-related vascular pathologies, such as reduced wound-healing capacity, impaired coronary collateral vessel formation, higher rates of transplant rejections, and embryonic vasculopathy and ensuing cardiovascular complications (Kolluru et al., 2012).

In our study, we have investigated the angiogenic response of MMECs in NG and HG conditions; then delved into explaining the possible molecular mechanism through the involvement of miR-34a and its downstream effectors; and investigated whether we could reverse these effects with metformin—the most widely used antihyperglycemic drug—which, based on data from both clinical and animal studies, has also been shown to protect endothelial function (Kinaan...
et al., 2015). Furthermore, miR-34a has been implicated as a tumor suppressor through the inhibition of angiogenesis (Yamakuchi et al., 2008). In addition, miR-34a has been shown to induce endothelial progenitor cell senescence and inhibit angiogenic capacity through the downregulation of sirtuin1 (Zhao et al., 2010). Data from cell-based studies and animal models indicate that sirtuin1 is highly expressed in the vasculature and has been shown to function as a deacetylase for a number of vascular genes, including eNOS, and modulates diabetes, ageing, and CVD-associated vascular dysfunction (Orimo et al., 2009; D’Onofrio et al., 2015). More importantly, it has been reported that the loss of sirtuin1 in ECs impairs migration and tube formation, thus limiting angiogenesis (Potente et al., 2007). Previously, we have shown that the decrease in sirtuin1 levels correlated with the induction of EC senescence in HG-exposed MMECs (Arunachalam et al., 2014).

In our present study, we have seen a significant increase in the levels of miR-34a in HG-exposed MMECs (Fig. 1) with a significant decrease in the levels of sirtuin1 and peNOS (Ser1177). Levels of peNOS (Thr165) and acetylated eNOS, both of which negatively regulate eNOS activity (Nisoli et al., 2005), were found to be significantly higher in HG-exposed MMECs. Inhibition of the HG-induced increase in miR-34a expression (using a miR-34a inhibitor) reversed the effects of HG on the levels of sirtuin1 and eNOS, indicating that the hyperglycemia-induced modulation of sirtuin1 levels and post-translational modification of eNOS operate through a miR-34a-dependent gene-regulatory mechanism.

The interactions between angiopoietins (Ang-1 and Ang-2) and their endothelium-specific tyrosine kinase receptor Tie2 are critical in the regulation of angiogenesis and vascular integrity (Fukuhara et al., 2010). Activation of Ang-1 and Tie2 signaling increases EC migration, sprouting, and angiogenesis, whereas activation of Ang-2 expression (an antagonist for Ang-1) inhibits Ang-1-mediated Tie2 stimulation and decreases EC migration, vascularization, and vessel maturation (Suri et al., 1998). Levels of proangiogenic Ang-1 decreased significantly, whereas levels of anti-angiogenic Ang-2 and TSP-1 increased significantly in HG-exposed MMECs (Fig. 2). The data from the current study indicate that the changes in these modulators of angiogenic potential result in a decrease in tubulogenic capacity, as evidenced by the marked decrease in the number of EC-derived branch points in our matrigel assay in the HG-exposed MMECs. However, inhibition of the HG-induced increase in miR-34a expression, by using a miR-34a inhibitor, significantly increased levels of Ang-1 while decreasing the levels of Ang-2 and TSP-1 (Fig. 2). Conversely, we have observed a significant increase in the number of EC-derived branch points in the HG-treated MMECs, which were also treated with the miR-34a inhibitor.

Metformin has been in clinical use for the treatment of T2DM for over 50 years, and its antidiabetic actions have been attributed to its inhibitory effect on mitochondrial complex 1 (El-Mir et al., 2000; Owen et al., 2000; Halimi, 2006; Madiraju et al., 2014). Preclinical in vivo studies and clinical data suggest that metformin possesses pleiotropic effects that protect the endothelium (Mather et al., 2001; Zhang et al., 2013; Arunachalam et al., 2014; Kinaan et al., 2015). However, the effect of metformin on miR-34a and its impact on endothelial function have not previously been studied. Treatment with metformin in HG-exposed MMECs reversed the HG-induced increase in miR-34a expression (Fig. 3) and subsequently increased the levels of sirtuin1 and peNOS
Ser1177) and decreased levels of acetylated eNOS, indicating that miR-34a is a molecular target for metformin through which it confers endothelial protection. Furthermore, the effects of metformin were mimicked by the miR-34a inhibitor. Similar comparative effects, a decrease in miR-34a expression with increases in sirtuin1 and peNOS levels, were also observed when MMECs were exposed to resveratrol in HG conditions (Supplemental Fig. 1).

A reduction and/or inhibition of sirtuin1 expression in ECs increase eNOS acetylation, which in turn reduces the generation of nitric oxide, thus leading to endothelial dysfunction. Conversely, sirtuin1 promotes endothelium-dependent vasodilation by targeting eNOS for deacetylation and enhances the bioavailability of NO, increasing cell proliferation and angiogenesis (Nisoli et al., 2005; Mattagajasingh et al., 2007; Potente et al., 2007; Arunachalam et al., 2010). In the present study, exposure of ECs to HG decreased the tubulogenic potential of MMECs possibly linked to the associated decrease in Ang-1 and increase in Ang-2 and TSP-1; treatment with metformin in HG-exposed MMECs increased
the level of pro-angiogenic Ang-1 and decreased the levels of anti-angiogenic Ang-2 and TSP-1, thereby improving the tubulogenic potential (Fig. 4). These data are in support of previous reports that decreased Ang-1 with increased Ang-2 expression was associated with vascular damage in the brains of mice with T2DM (Cui et al., 2011).

We also further investigated the role of miR-34a in the regulation of angiogenesis using a miR-34a mimic. The presence of a miR-34a mimic in NG-exposed MMECs significantly decreased the levels of sirtuin1 and peNOS (Ser1177) (Fig. 5), as well as decreasing the levels of Ang-1 and increasing the levels of Ang-2 and TSP-1, and decreased the tubulogenic capacity of these MMECs (Fig. 6). This effect was similar to that observed under HG conditions in the absence of a miR-34a mimic. In the presence of a miR-34a mimic, metformin did not effectively reverse the HG-induced effects on sirtuin1, peNOS (Ser1177), and tubulogenic potential in MMECs, indicating that the endothelial-protective and angiogenic potential of metformin operates through a miR-34a-dependent regulation of downstream sirtuin1, eNOS, Ang-1, Ang-2, and TSP1 expression. In addition, our study further evaluated the possible involvement of the metabolic sensor, AMPK, the cellular fuel gauge, in mediating the cellular effects of metformin. Our data demonstrate that AMPK silencing rendered metformin treatment ineffective in modulating the levels of miR-34a, sirtuin1, and its downstream signaling in HG-exposed MMECs, and thus provides support for the AMPK-dependent action of metformin (Supplemental Fig. 1). Metformin has also been reported to increase SIRT1 level/activity, or, in part, via the upstream kinase, serine-threonine liver kinase B1/AMPK pathway, and thereby protect the retinal endothelium (Zheng et al., 2012). It has also become increasingly apparent that the regulation of AMPK and SIRT1 is interdependent (Ruderman et al., 2010). For instance, data from a recent study indicate that inhibition of miR-34a results in a sirtuin1/AMPK-dependent attenuation of steatosis in hepatocytes and liver tissue of high-fat diet–fed mice, and that AMPK is an important modulator of miR-34a and its effects on sirtuin1 and its target genes (Ding et al., 2015). Collectively, these data and that from the current study indicate that miR34a is an important target for the prevention of diabetes-related vascular disease, but, nonetheless, that further studies are also required to better understand how the miR-34a and AMPK/sirtuin1 signaling pathways are regulated and dysregulated in diabetes.

An elevation in miR-34a expression has also been linked to reduced sirtuin1 expression in obesity and arteries from aged human and mice (Li et al., 2011; Choi et al., 2013; Fu et al., 2014) and accelerated apoptosis of cardiomyocytes in neonatal and adult mouse hearts (Yang et al., 2015). In conclusion, and as summarized in Fig. 6G, our results demonstrate that hypoglycemia-mediated induction of miR-34a results in a reduction of sirtuin1, reduced eNOS function that results in impaired angiogenesis. In addition, our results provide mechanistic evidence that their therapeutic intervention with metformin reverses hyperglycemia–associated impaired angiogenesis possibly through the modulation of miR-34a levels, which in turn regulates sirtuin1, AMPK, and eNOS activity, thus shedding more light on potential new therapeutic approaches to combat diabetes–associated CVD.

Acknowledgments

The authors thank Suparna Ghosh for valuable technical assistance.

Authorship Contributions

Participated in research design: Arunachalam, Ding. Conducted experiments: Arunachalam, Lakshmanan (for revised version). Performed data analysis: Arunachalam, Lakshmanan (for revised version).

Wrote or contributed to the writing of the manuscript: Arunachalam, Samuel, Triggle, Ding.

References


